- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Somatic Mutations in the ATRX Gene Reported for the First Time in Pheochromocytomas/ Paragangliomas
October 13th 2014, 7:58am
Somatic mutations in the ATRX gene are observed in about 13% of pheochromocytomas/paragangliomas, the first such report of somatic ATRX mutations in these tumors.
Dr. Kulke on Unanswered Questions Surrounding the Treatment of NETs
October 13th 2014, 7:21am
Matthew Kulke, MD, comments on some unanswered questions surrounding the treatment of neuroendocrine tumors (NETs).
CDKN1B Mutation May Be Linked to Worse Survival in GEP NETs
October 13th 2014, 6:16am
Low nuclear expression of CDKN1B, a cyclin-dependent kinase inhibitor gene that encodes p27, in gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) appears to be associated with a worse prognosis.
Few Agents Better Than Somatostatin Analogs for Symptom Control in Carcinoid Syndrome
October 11th 2014, 3:04pm
Somatostatin analogs remain the mainstay of medical therapy for symptom control in patients with carcinoid syndrome.
Subcutaneous Octreotide May Offer Better Option for Managing NETS Symptoms
October 11th 2014, 7:15am
A subcutaneous depot formulation of octreotide has a rapid onset, greater bioavailability, and a similar duration of effect compared with intramuscular octreotide long-acting repeatable.
Axitinib Shows Promise in Carcinoid Tumors
October 10th 2014, 3:10pm
The rate of PFS with axitinib in patients with advanced carcinoid tumors is promising.
Everolimus Improves Outcomes in Pancreatic Neuroendocrine Tumors
October 10th 2014, 2:08pm
Treatment with the mTOR inhibitor everolimus improved overall survival by 6.34 months over placebo for patients with pancreatic neuroendocrine tumors.
Dr. Reidy-Lagunes on Determining the Site of Unknown Primary in Metastatic NETs
October 10th 2014, 1:28pm
Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis looking at a practical method of determining the site of unknown primary in metastatic neuroendocrine tumors (NETs).
Dr. Pommier Discusses Challenges Associated With the Treatment of Carcinoid Syndrome
October 10th 2014, 12:52pm
Rodney F. Pommier, MD, professor of surgery, director, Neuroendocrine Tumor Program, Oregon Health & Science University, discusses challenges associated with the treatment of carcinoid syndrome.
Combination Therapies, Novel Targeted Agents Are Focus of Pancreatic NET Studies
October 10th 2014, 12:29pm
Selection of first-line treatments and the rational sequencing of therapies are among the unresolved questions in the treatment of pancreatic neuroendocrine tumors.
Dr. Yao on Takeaways From the RADIANT-3 Trial
October 10th 2014, 10:07am
James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses key takeaways from the RADIANT-3 trial for a community oncologist.
Dr. Kunz on Sequencing Agents for Pancreatic NETs
October 10th 2014, 10:02am
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.
Targeting Src Adds No Benefit in VEGF-Resistant Metastatic Renal Cell Carcinoma
October 6th 2014, 5:16am
Adding saracatinib to vascular endothelial growth factor (VEGF)-targeted therapy did not improve response rates or overall survival while adding to toxicity in VEGF-resistant metastatic renal cell carcinoma
Dr. Saab on a Phase II Study of the Oncolytic Virus Reolysin for Pancreatic Cancer
September 30th 2014, 1:07pm
Tanios Bekaii-Saab, MD, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.
Durable Responses Observed with Nivolumab in Previously Treated mRCC
September 30th 2014, 11:36am
Durable responses were obtained with the immune checkpoint inhibitor nivolumab, with a manageable safety profile, in a phase II dose-ranging trial conducted in patients with previously treated metastatic renal cell carcinoma (mRCC).
New Data Provide Insight Into Optimal Pre-Chemo Treatments for mCRPC
September 30th 2014, 11:27am
The combination of abiraterone acetate and prednisone has demonstrated a statistically significant improvement in overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) who had not received prior treatment with chemotherapy
Dabrafenib/Trametinib Combo Improves Survival Over Vemurafenib in Phase III COMBI-v Trial
September 30th 2014, 9:04am
Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy
Expanded 80405 Study Mutation Analysis Fails to Resolve Targeted Therapy Quandary in mCRC
September 30th 2014, 8:49am
All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.
Dr. Motzer on a Phase II Trial of Nivolumab for mRCC
September 30th 2014, 6:45am
Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.
Combination BRAF, MEK Inhibition "New Standard" for Previously Untreated BRAF-Mutant Melanoma
September 29th 2014, 10:16am
Inhibiting BRAF and MEK at the same time improves progression-free survival (PFS) more so than BRAF inhibition alone in patients with BRAF V600 mutation-positive metastatic melanoma, according to results of a phase III placebo-controlled trial.